Aquestive Therapeutics, INC 10-Q quarterly reports

Aquestive Therapeutics announces the termination of an executive employment agreement, with the executive transitioning to Corporate Secretary.

Aquestive Therapeutics reported a significant increase in net loss and revenue decline for Q3 2025, while its lead product candidate Anaphylm progresses towards a January 2026 FDA decision, and Libervant's U.S. market access was vacated by a court ruling.

Aquestive Therapeutics, Inc. reported a significant increase in net loss and a substantial decline in revenue for the second quarter and first half of 2025, primarily due to one-time revenue recognition in the prior year and the halted U.S. market access for Libervant, while its Anaphylm NDA was accepted by the FDA with a January 2026 PDUFA date.

Aquestive Therapeutics announces its Q1 2025 financial results and provides an update on its key product candidates, including the submission of the NDA for Anaphylm.

Aquestive Therapeutics' Q3 2024 results show a 22% year-to-date revenue increase, driven by license and royalty revenue, despite a decrease in manufacturing revenue.

Aquestive Therapeutics saw a significant revenue increase in Q2 2024, driven by one-time gains, despite a decrease in manufacturing revenue.

Aquestive Therapeutics' Q1 2024 results show increased revenue and a significant cash boost from a public offering, alongside advancements in their drug pipeline.